Thereby, we successfully demonstrated that tyrosine hydroxylase Ser40 phosphorylation can be upregulated via PDE inhibition, proving the therapeutic potential of PDE inhibition to replenish striatal dopamine in situations where dopamine neurotransmission is affected, such as seen in Parkinson’s disease. This evidence concerns the gene TH and Parkinson disease.